Although ARID1A is not included in our sequencing panel, it is possible that gastric adenocarcinomas with TP53 mutations in our sample set follow an alternative pathway to that chromatin modifying gene-associated cancers. This evidence concerns the gene ARID1A and gastric adenocarcinoma.